arguably the low rate of clinical trial enrollment. Recent reports estimate only 2% to 5% of adults diagnosed with cancer participate in clinical trials, although up to 20% of adults may be eligible for disease-specific clinical trial participation. 4 - 6
Search Results
Lydia T. Madsen, Deborah A. Kuban, Seungtaek Choi, John W. Davis, Jeri Kim, Andrew K. Lee, Delora Domain, Larry Levy, Louis L. Pisters, Curtis A. Pettaway, John F. Ward, Christopher Logothetis, and Karen E. Hoffman
Joseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, Timothy A. Lin, Austin B. Miller, Amit Jethanandani, Andres F. Espinoza, Dario Pasalic, Vivek Verma, Noam A. VanderWalde, Benjamin D. Smith, Grace L. Smith, C. David Fuller, Prajnan Das, Bruce D. Minsky, Claus Rödel, Emmanouil Fokas, Reshma Jagsi, Charles R. Thomas Jr, Ishwaria M. Subbiah, Cullen M. Taniguchi, and Ethan B. Ludmir
(full normal functioning) to 0 (dead). 7 – 9 Patients with ECOG PS 0 to 1 are broadly considered to have a good PS and tend to have better clinical and survival outcomes. 2 , 10 , 11 Such patients have been historically favored in clinical trials, which
Norma F. Kanarek, Hua-Ling Tsai, Sharon Metzger-Gaud, Dorothy Damron, Alla Guseynova, Justin F. Klamerus, and Charles M. Rudin
A fundamental goal of cancer centers is to improve cancer care through the design and conduct of therapeutic clinical trials. 1 Progress in prevention and control of cancer depends on research that identifies treatments that prevent or delay
Nicholas G. Zaorsky, Ying Zhang, Vonn Walter, Leila T. Tchelebi, Vernon M. Chinchilli, and Niraj J. Gusani
Background A clinical trial is defined by the NIH 1 as “a research study in which one or more human subjects are prospectively assigned to one or more interventions…to evaluate the effects of those interventions on health-related biomedical or
Shane Lloyd, Daniela L. Buscariollo, Cary P. Gross, Danil V. Makarov, and James B. Yu
to be allocated to diseases that pose a greater burden, 5 the relationship between this burden and projected enrollment in cancer randomized clinical trials (RCTs) has never been formally studied. How RCT enrollment from all funders is distributed
Marjorie G. Zauderer and Lee M. Krug
clinical trials are testing agents against a wide range of relevant targets ( Table 1 ). Table 1 Novel Agents in Clinical Trials Inhibitors of Cellular Functions Numerous small molecule inhibitors used to treat other solid tumors have
Omar Abdel-Rahman, Hatim Karachiwala, and Jacob C. Easaw
launched platform that allows researchers access to deidentified clinical trial datasets. 7 It thus represents an excellent opportunity to examine this question with limited confounders. To minimize heterogeneity of the sample used for this analysis, we
Figure 1 (A) Aggregate distribution of patient accruals to therapeutic trials, by sponsor. A total of 16,018 patient accruals were reported. (B) Aggregate distribution of sponsorship for all active therapeutic clinical trials. A total of 6
Pam James, Patricia Bebee, Linda Beekman, David Browning, Mathew Innes, Jeannie Kain, Theresa Royce Westcott, and Marcy Waldinger
In response to perceived increases in clinical trial complexity and concomitant greater demands on staffing resources, the University of Michigan Comprehensive Cancer Center (UMCCC) Clinical Trials Office (CTO) endeavored to quantify the amount of
Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland
Clinical trials in oncology are more likely to fail than those in any other disease area. 1 Many fail in phase III, after great expense and many years of effort. 2 , 3 Assuming that most decisions to proceed to phase III are based on reasonable
